NCT05023525View on ClinicalTrials.gov

A Study of Safety, Tolerability, and Pharmacokinetics of Single Ascending Dosed of HSK31858 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

October 28, 2021

Primary Completion Date

April 19, 2022

Study Completion Date

August 16, 2022

Conditions
Healthy
Interventions
DRUG

HSK31858, tablet

Starting dose in single ascending dose: 5 mg

DRUG

Placebo, tablet

Matching placebo

Trial Locations (1)

Unknown

Nucleus Network Pty Ltd, Melbourne

All Listed Sponsors
collaborator

Haisco Pharmaceutical(Australia) Pty Ltd.

UNKNOWN

lead

Haisco Pharmaceutical Group Co., Ltd.

INDUSTRY

NCT05023525 - A Study of Safety, Tolerability, and Pharmacokinetics of Single Ascending Dosed of HSK31858 in Healthy Volunteers | Biotech Hunter | Biotech Hunter